Skip to main content

Table 6 Median Fasting Lipid and Metabolic Parameters at Baseline and Week 48

From: A randomized, controlled trial of initial anti-retroviral therapy with abacavir/lamivudine/zidovudine twice-daily compared to atazanavir once-daily with lamivudine/zidovudine twice-daily in HIV-infected patients over 48 weeks (ESS100327, the ACTION Study)

 

ABC/3TC/ZDV

N = 138

ATV+3TC/ZDV

N = 140

Median (range)

Number Tested

(Baseline, Week 48)

Baseline

Week 48

Number Tested

(Baseline, Week 48)

Baseline

Week 48

TC (mg/dL)

131, 93

162

(95–255)

176

(102–305)

137, 93

160

(71–276)

171

(68–288)

LDL (mg/dL)

127, 89

98

(6–165)

99

(20–198)

133, 92

97

(31–200)

101.5

(10–200)

HDL (mg/dL)

131, 93

36.5

(6–74)

44

(21–75)

135, 93

33

(7–77)

44

(18–90)

TG (mg/dL)

131, 93

113

(38–621)

126

(42–1231)

137, 93

117 (41–559)

110

(44–407)

Glucose (mg/dL)

119, 91

95

(60–199)

98

(5–268)

126, 93

89.5

(58–131)

95

(72–166)

Insulin (μIU/mL)

117, 79

10

(2–128)

13

(2–56)

119, 83

10

(2–61)

12

(4–132)

HOMA-IR+

110, 83

2.2

(0.4–37.5)

2.9

(0.4–17.3)

112, 87

2.4

(0.4–19.5)

3

(0.9–51.6)

QUICKI++

110, 83

0.59

(0.34–1.05)

0.54

(0.38–1.00)

112, 87

0.58

(0.37–1.00)

0.54

(0.32–0.77)

  1. +HOMA-IR = [Fasting Insulin (μIU/mL) × Fasting Glucose (mg/dL))/(22.5 × 18)];
  2. ++QUICKI = 1/[log Fasting Insulin (μIU/mL)] + [log Fasting Glucose (mg/dL)]
Back to article page

AIDS Research and Therapy

ISSN: 1742-6405

Contact us